Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Geller
    Geller
  3. Geyer
    Geyer
  4. Giralt
    Giralt
  5. Myskowski
    Myskowski
  6. Palomba
    Palomba
  7. Park
    Park
  8. Perales
    Perales
  9. Pulitzer
    Pulitzer
  10. Sabbatini
    Sabbatini

Groups

  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (6)
  5. Executive Committee, Center for Hematologic Malignancies (3)
  6. Population Sciences Research Program (3)
  7. Epidemiology and Biostatistics (2)
  8. Adult Leukemia (1)
  9. Advanced Practice Providers (1)
  10. Biostatistics Service (1)
Search Within
  1. "Lymphoma"
  2. "2019"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (2)
  3. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (6)
  5. Executive Committee, Center for Hematologic Malignancies (3)
  6. Population Sciences Research Program (3)

More Groups

People
  1. Anas Younes (3)
  2. Steven Horwitz (2)
  3. Ai Ni (1)
  4. Andrew Zelenetz (1)
  5. Bianca Santomasso (1)
  6. Connie Batlevi (1)

More People

Years
  1. 2019 (6)
Publications
  1. The Lancet Haematology (3)
  2. Journal of Investigative Dermatology (1)
  3. Lancet (1)
  4. Value in Health (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment
    Meeting Abstract

    Geller, S.; Hollmann, T. J.; Horwitz, S. M.; Myskowski, P. L.; Pulitzer, M.
    Journal of Investigative Dermatology (2019)

    Fulltext@MSK | Save
  • Will GALEN become more RELEVANT?
    Editorial

    von Keudell, G.; Younes, A.
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations
    Journal Article

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Rabe, K. G.; Byrd, J. C.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study
    Journal Article

    Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial
    Journal Article

    Horwitz, S.; O'Connor, O. A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Lancet (2019)

    Fulltext@MSK | Save